Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/Optometrymhn Vizz (aceclidine) Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PMN.302

    Clinical Policy: Aceclidine (Vizz)

    Customize your policy alerts

    Sign up for mhn Policy CP.PMN.302 alerts

    Get alerted when Policy CP.PMN.302 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing medical necessity and prior authorization criteria for aceclidine ophthalmic solution (Vizz) for treatment of presbyopia for Centene-affiliated health plans.

    Policy Summary
    Payermhn
    PolicyClinical Policy: Aceclidine (Vizz)
    Policy CodePolicy CP.PMN.302
    Change TypeNo material changes
    Effective Date12.01.25
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing diagnosis of presbyopia, provider specialty, age 45-75 at initiation, failure of corrective lenses unless contraindicated, no concurrent Vuity/Qlosi, and dose ≤2 drops/eye/day.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    45-75age range for initial therapy eligibility
    1.44%product concentration
    2 drops/eye/daymaximum daily dosing
    12 monthsapproval duration

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial Therapy - Presbyopia

    Covered when ALL of the following are met for Presbyopia:

    Presbyopia initial criteria: 1. Diagnosis of presbyopia; 2. Prescribed by or in consultation with an optometrist or ophthalmologist; 3. Age between 45 and 75 years at the time of therapy initiation; 4. Failure of corrective eyeglasses or contact lenses to resolve the presbyopia symptoms unless contraindicated or clinically significant adverse effects are experienced; 5. Vizz is not prescribed concurrently with Vuity or Qlosi; 6. Dose does not exceed 2 drops per eye per day.

    Approval duration: 12 months

    Continued Therapy - Presbyopia

    Covered when ALL of the following are met for Continued Therapy:

    Presbyopia continued therapy criteria: 1. Member meets one of the following (a or b): a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria; b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations; 2. Member is responding positively to therapy; 3. If request is for a dose increase, new dose does not exceed 2 drops per eye per day.

    Approval duration: 12 months

    Other diagnoses/indications

    Other diagnoses/indications:

    Other indications pathway: 1. If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy, refer to the applicable no-coverage or non-formulary policy for the relevant line of business (commercial, health insurance marketplace, or Medicaid) as listed in the policy; OR 2. If the requested use (diagnosis, age, dosing regimen) is not listed under the policy's exclusions and criterion 1 does not apply, refer to the off-label use policy for the relevant line of business.

    See referenced policies: CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, CP.PMN.16, CP.CPA.09, HIM.PA.154, CP.PMN.53

    Requests for use of aceclidine (Vizz) for non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless there is sufficient documentation of efficacy and safety per the applicable off‑label use policies for the member’s line of business.

    Authorization for requests involving non‑FDA approved indications is contingent on submission of supporting clinical documentation that demonstrates efficacy and safety in accordance with the referenced off‑label use policies (see CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid) or the member’s evidence of coverage documents.

    Provider Actions & Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Vizz. Providers must obtain prior authorization and submit documentation demonstrating that all approval criteria are met, including diagnosis, treating provider specialty, patient age, prior therapy attempts (step therapy), dosing, and absence of contraindicated concurrent medications.

    • Prior authorization required for Vizz (CP.PMN.302).
    • Ensure submission includes evidence of diagnosis, provider specialty, patient age, prior corrective eyewear/contact lens failure (or contraindication), medication dosing, and statement re: concurrent use with Vuity®/Qlosi™.
    • Approval duration: 12 months.
    Step Therapy

    Step Therapy Requirement

    Step therapy applies: members must have tried and failed corrective eyeglasses or contact lenses for presbyopia prior to approval of Vizz, unless there is a documented contraindication or clinically significant adverse effect that prevents their use. Note: For Illinois HIM requests, the step therapy requirement does not apply effective 01/01/2026 per IL HB 5395.

    • Step therapy: documented failure of corrective eyeglasses/contact lenses required prior to Vizz approval unless contraindicated.
    • IL exception: IL HB 5395 removes step therapy for Illinois HIM requests as of 2026-01-01.
    Documentation Required

    Required Documentation

    Providers must submit office chart notes, relevant diagnostic test results, and any other clinical information that supports the member meets ALL policy criteria. Missing or incomplete documentation may result in denial of the prior authorization request.

    • Required documentation: office/clinic notes, diagnostic test results, date of birth to confirm age, documentation of prior corrective eyewear/contact lens trial or contraindication, medication dosing, and prescriber specialty/consultation notes.
    • If documentation is not provided or does not demonstrate all required criteria, the request may be denied or returned for additional information.
    Denial Risk

    Documentation Triggers and Denial Risk

    Documentation triggers — requests lacking required documentation or failing to show that approval criteria are met will be subject to denial. Examples include absence of documentation of failed corrective eyewear/contact lens therapy (or contraindication), missing prescriber specialty, patient age outside 45–75 years, evidence of concurrent Vuity® or Qlosi™ use, or dosing above 2 drops per eye per day.

    • Denial risk if: no proof of prior corrective eyewear/contact lens failure and no contraindication documented.
    • Denial risk if: prescriber is not an optometrist/ophthalmologist or consultation documentation is missing.
    • Denial risk if: patient age <45 or >75 at therapy initiation.
    • Denial risk if: concurrent prescription of Vuity® or Qlosi™ is noted.
    • Denial risk if: dosing exceeds 2 drops per eye per day.

    Definitions / Product Details

    Vizz (aceclidine) — key facts
    Product nameVizz (aceclidine)
    Drug classCholinergic agonist (ophthalmic solution)
    Concentration1.44% (ophthalmic solution, single‑dose vial)
    Dosing regimenInstill 1 drop in each eye; wait 2 minutes and may instill a second drop in each eye once daily
    Maximum daily dose2 drops per eye per day
    FDA‑approved indicationTreatment of presbyopia

    Background

    Aceclidine (Vizz) is a cholinergic agonist ophthalmic solution approved by the FDA for the treatment of presbyopia. It is supplied as a 1.44% ophthalmic solution in single‑dose vials. The dosing regimen is to instill 1 drop in each eye once daily, with the option to instill a second drop after 2 minutes if needed, for a maximum of 2 drops per eye per day.

    Policy Summary
    Payermhn
    PolicyClinical Policy: Aceclidine (Vizz)
    Policy CodePolicy CP.PMN.302
    Change TypeNo material changes
    Effective Date12.01.25
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing diagnosis of presbyopia, provider specialty, age 45-75 at initiation, failure of corrective lenses unless contraindicated, no concurrent Vuity/Qlosi, and dose ≤2 drops/eye/day.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions & Authorization RequirementsDefinitions / Product DetailsBackground